公开(公告)号：US20240033340A1

公开(公告)日：2024-02-01

申请号：US18329696

申请日：2023-06-06

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  A61K39/395 ,  C07K16/28 ,  C07K14/005 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/395 ,  A61K39/39541 ,  C07K16/2878 ,  A61K39/3955 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/20034 ,  A61K2039/505

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20220152192A1

公开(公告)日：2022-05-19

申请号：US17454108

申请日：2021-11-09

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Dapeng LI

IPC: A61K39/145 ,  A61K47/68 ,  A61K51/10 ,  C07K16/28 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C12N5/0784 ,  C12N7/00

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

公开(公告)号：US20220054609A1

公开(公告)日：2022-02-24

申请号：US17447607

申请日：2021-09-14

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Gerard ZURAWSKI

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/46

Abstract: Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.

公开(公告)号：US20190231865A1

公开(公告)日：2019-08-01

申请号：US16372832

申请日：2019-04-02

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Dapeng LI

IPC: A61K39/145 ,  C12N7/00 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C07K14/195 ,  C12N5/0784 ,  A61K51/10 ,  A61K47/68 ,  C07K14/005

CPC classification number: A61K39/145 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/5154 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C12N5/0639 ,  C12N7/00 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.